Vivanza Biosciences Reports Significant Operational Challenges in March 2025 Financial Results

Vivanza Biosciences has recently reported its financial results for the quarter ending March 2025, revealing notable challenges within its operations. The company, classified as a microcap in the miscellaneous industry, has experienced a negative financial performance during this period.
The operating profit, measured as PBDIT, reached its lowest point in the last five quarters at Rs -0.96 crore, indicating a concerning trend in operational efficiency. Similarly, the profit before tax, less other income, also hit a low of Rs -1.04 crore, reflecting ongoing difficulties in generating positive financial outcomes.

Earnings per share (EPS) for the quarter stood at Rs -0.25, marking the lowest level in the past five quarters and suggesting a decline in profitability that impacts shareholder returns. Additionally, the debtors turnover ratio has decreased to 0.92 times over the last half-year periods, indicating a slowdown in the company's ability to settle its debts.

In light of these developments, Vivanza Biosciences has undergone an adjustment in its evaluation, with its score shifting to -7 from -8 over the past three months.

Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.